Rapid and sensitive Lethal Factor immunoassay for early diagnosis of anthrax - CEA - Commissariat à l’énergie atomique et aux énergies alternatives Accéder directement au contenu
Poster De Conférence Année : 2022

Rapid and sensitive Lethal Factor immunoassay for early diagnosis of anthrax

Résumé

Bacillus anthracis is a gram-positive, spore forming bacterium responsible of anthrax in humans and animals. It is considered one of the most potent and dangerous biological weapon and in this regard has been classified as a category A potential biological warfare agent by the United states Centers for Disease Control and prevention (CDC). Very early after infection components of anthrax toxin: the protective antigen (PA), the lethal factor (LF) and the edema factor (EF), are secreted and circulate in blood before bacteria are detectable and before emergence of any clinical signs. Early and rapid diagnosis is essential to improve survival, particularly in cases of anthrax inhalation almost 100% fatal without treatment. In this context, we have produced monoclonal antibodies against LF and developed sensitive and rapid ELISA (result time ≤ 3 hours) and lateral flow immunoassay (LFIA, result time ≤ 30 min). A limit of detection (LoD) of 1 pg/ml of LF by ELISA and 31 pg/ml by LFIA were determined in buffer or two-fold diluted human serum. The analytical sensitivity of these tests appear suitable for early diagnosis of anthrax before the bacteria are detectable in blood and disseminate.

Mots clés

Fichier non déposé

Dates et versions

cea-04482891 , version 1 (28-02-2024)

Identifiants

  • HAL Id : cea-04482891 , version 1

Citer

Benjamin Morin, Anne Wijkhuisen, Christèle Gobillon, Elise Yang, Stéphanie Simon, et al.. Rapid and sensitive Lethal Factor immunoassay for early diagnosis of anthrax. 5th International Conference CBRNE Research and Innovation, May 2022, Lille, France. ⟨cea-04482891⟩
13 Consultations
0 Téléchargements

Partager

Gmail Facebook X LinkedIn More